Ischemic Heart Disease News and Research

RSS

OrbusNeich completes enrollment in Combo Bio-engineered Sirolimus Eluting Stent clinical trial

OrbusNeich today announced at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 in Washington the completion of patient enrollment in the randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) with 183 patients included at sites in Asia, Australia, Europe and South America.

24 Sep 2010

Methodist surgeons perform multiple cardiac vessel bypasses through small single incision

Surgeons at the Methodist DeBakey Heart & Vascular Center perform multiple cardiac vessel bypasses through a single, small incision in the patient's side, reducing pain, recovery time and risk for infection.

15 Sep 2010

New VA regulation helps to get recognition, treatment for three disorders in Agent Orange exposure

A new VA regulation adding three health conditions to the list of those presumed to have been caused by exposure to the toxic defoliant Agent Orange during the Vietnam War was published this week. Pending a 60-day congressional review, the regulation will make some 200,000 veterans eligible for VA benefits over the next year and a half.

4 Sep 2010

VA prepares to expand Agent Orange related claims for Vietnam veterans

The Washington Post: "The Department of Veterans Affairs is preparing for more than 150,000 Vietnam War veterans to apply for benefits in the next 18 months thanks to new regulations making it easier to compensate for health problems caused by exposure to the Vietnam-era defoliant Agent Orange. Changes set for publication in Tuesday's Federal Register could result in payouts of about $42 billion in the next decade, VA said.

2 Sep 2010

Final regulation to aid Veterans exposed to herbicides published in 'Federal Register'

Veterans exposed to herbicides while serving in Vietnam and other areas will have an easier path to access quality health care and qualify for disability compensation under a final regulation that will be published on August 31, 2010 in the Federal Register by the Department of Veterans Affairs (VA). The new rule expands the list of health problems VA will presume to be related to Agent Orange and other herbicide exposures to add two new conditions and expand one existing category of conditions.

31 Aug 2010

VA's liabilities grow as agency expands list of diseases linked to Agent Orange

Politico looks at a new fight brewing over Agent Orange and how it affects programs for Vietnam Veterans. "It's a world turned upside-down from decades ago when returning soldiers had to fight to get attention for deadly lymphomas linked to the herbicide. Now the frailties of men in their 60s — prostate cancer, diabetes, heart disease — lead the list of qualified Agent Orange disabilities, and the result has been an explosion in claims — and the government's liability.

31 Aug 2010

Study finds black women with SLE develop cardiovascular disease at early age

A recent study by researchers at Penn State College of Medicine found significant racial disparities in the age of systemic lupus erythematosus (SLE) patients at the time of hospital admission for cardiovascular disease (CVD) events and CVD-related death. Black women were youngest to both be admitted with CVD and to have an in-hospital death due to CVD.

20 Aug 2010

HDL does not predict heart attack risk after dramatic statin therapy: Study

People with high levels of "good cholesterol," HDL-C, tend to have fewer heart attacks, but HDL-C may offer little protection to people who take statins to lower harmful LDL cholesterol, researchers reported July 21. At Brigham and Women's Hospital in Boston, Dr. Paul Ridker and colleagues analyzed a large study of healthy people who took the statin CRESTOR® (rosuvastatin calcium) to prevent heart attacks. They found that in this group, having high HDL-C was a bad predictor of heart attack risk.

2 Aug 2010

Researchers receive $4.7M contract to develop drugs to improve soldiers' performance at high altitude

Jonathan Stamler, MD, Director of the Institute for Transformative Molecular Medicine and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at the Case Western Reserve University and University Hospitals Harrington-McLaughlin Heart & Vascular Institute, has recently received a $4.7 million contract from the Defense Advanced Research Projects Agency to fund the development of a new class of drugs that will selectively dilate blood cells under hypoxia (lack of oxygen in the body's tissues) and thereby enhance soldiers' performance at high altitude.

31 Jul 2010

Devax's AXXESS Biolimus A9 Eluting Coronary Bifurcation Stent System receives CE Mark approval

Devax, Inc. announced today the company received CE Mark for its AXXESS™ Biolimus A9® Eluting Coronary Bifurcation Stent System, allowing the company to initiate sales in the European Union and other countries that recognize the CE Mark.

29 Jul 2010

VA to develop fully automated, online system for handling disability compensation claims

Secretary of Veterans Affairs Eric K. Shinseki announced today plans to develop a fully automated, online system for handling Veterans' disability compensation claims. More than a simple digitization of existing paper-based claims, the new system is part of VA's modernization of the end-to-end processing workflow. Automation will substantially reduce processing time and increase accuracy while simplifying the way that Veterans interact with the claims process.

3 Jul 2010

BSP receives European CE conformance mark for HyperQ AD-100 add-on system

BSP, which develops and commercializes advanced products for the non invasive, accurate diagnosis of heart diseases, announced today that its Add-On product, the HyperQ AD-100, intended for improved diagnostic performance of Stress ECG, has been granted the European CE conformance mark.

30 Jun 2010

Most men admitted for heart attack had erectile dysfunction

Seven out of 10 men admitted to hospital for a heart attack (acute ST segment elevation myocardial infarction (STEMI)) had erectile dysfunction (ED) in the six months prior to their admission according to new data presented today at the World Congress of Cardiology (WCC) Scientific Sessions in Beijing, China.

19 Jun 2010

Women receive greater clinical benefit from CRT-Ds than men: Study

Boston Scientific Corporation today announced results from a sub-analysis of the MADIT-CRT trial data that showed women received a greater clinical benefit from its cardiac resynchronization therapy defibrillators (CRT-Ds) than men. The results were presented during the 17th Cardiostim World Congress by Jonathan Steinberg, M.D., Chief of Cardiology and Director of the Al-Sabah Arrythmia Institute, St. Luke's-Roosevelt Hospital Center, New York.

18 Jun 2010

Economic, clinical benefits of HyperQ stress test presented at International Congress on Electrocardiology

BSP Biological Signal Processing Ltd., develops and markets innovative systems for non-invasive diagnosis and monitoring of Ischemic Heart Disease based on its proprietary HyperQ technology. BSP recently presented the results of a study on the economic and clinical benefits of the HyperQ stress test in the diagnosis and management of coronary heart disease at the International Congress on Electrocardiology on June 4th, 2010.

7 Jun 2010

Bioheart to establish two Centers of Excellence to provide cell therapy procedures for patients with CHF, PAD

Bioheart, Inc., announced today plans for establishing two Centers of Excellence in the Middle East to provide its cell therapy procedures to patients suffering from congestive heart failure and peripheral arterial disease. Dr. Karl E. Groth, Chairman and CEO, and Peggy A. Farley, Chief Operating and Financial Officer, are now in that region holding discussions and performing site inspections.

29 May 2010

Medtronic’s Resolute zotarolimus-eluting stent as effective as Xience V everolimus-eluting stent: Study

The highly anticipated first results of the RESOLUTE All Comers study were presented today during the late-breaking clinical trial session of the 2010 EuroPCR meeting. In this novel 2,292-patient randomized trial, the Resolute zotarolimus-eluting stent from Medtronic, Inc. was found to be as safe and effective as the Xience® V everolimus-eluting stent from Abbott Laboratories.

26 May 2010

Exposure to fine particulate matter can trigger cardiovascular deaths, heart attacks

The scientific evidence linking air pollution to heart attacks, strokes and cardiovascular death has "substantially strengthened," and people, particularly those at high cardiovascular risk, should limit their exposure, according to an updated American Heart Association scientific statement.

11 May 2010

$SBUMC adds Toshiba Aquilion ONE \320-detector row CT system with pediatric imaging capabilities$

SBUMC adds Toshiba Aquilion ONE \320-detector row CT system with pediatric imaging capabilities

A new state-of-the art computed tomography (CT) scanner that provides physicians with precise images of internal organs with a single rotation of the gantry is now in operation at Stony Brook University Medical Center (SBUMC), adding to the hospital's advanced scanner technology.

15 Apr 2010

Researchers evaluate new treatment for coronary heart disease

Some patients with heart muscles seriously affected by coronary heart disease may soon be able to benefit from an innovative treatment.

13 Apr 2010